In December 2024, the University of Iowa's Clinical Research Unit (CRU) underwent an FDA inspection as part of a clinical trial for the new medication, oral Fabhalta, aimed at treating C3 glomerulopathy (C3G). Due to the ultra-rare nature of C3G, the CRU saw patients from all over the United States and Canada and was the number one enroller for the clinical research trial globally.  “Due to our recruitment, our site was selected for and completed FDA Inspection,” Carla Nester, MD, MSA, FASN shared.